P S Schein
About
In The Last Decade
P S Schein
16 papers receiving 375 citations
Peers
Comparison fields: 5 of 63
- Oncology 315
- Radiology, Nuclear Medicine and Imaging 189
- Pulmonary and Respiratory Medicine 100
- Molecular Biology 55
- Orthopedics and Sports Medicine 52
Countries citing papers authored by P S Schein
This map shows the geographic impact of P S Schein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P S Schein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P S Schein more than expected).
Fields of papers citing papers by P S Schein
This network shows the impact of papers produced by P S Schein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P S Schein. The network helps show where P S Schein may publish in the future.
Co-authorship network of co-authors of P S Schein
This figure shows the co-authorship network connecting the top 25 collaborators of P S Schein. A scholar is included among the top collaborators of P S Schein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P S Schein. P S Schein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 195 | |
| 2 | Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer | 48 |
| 3 | 39 | |
| 4 | 3 | |
| 5 | 1 | |
| 6 | Preclinical evaluation of WR-151327: an orally active chemotherapy protector. | 16 |
| 7 | 1 | |
| 8 | 1 | |
| 9 | Cisplatin in patients with gastric cancer: a Cancer and Leukemia Group B phase II study. | 17 |
| 10 | 8 | |
| 11 | Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer. | 9 |
| 12 | Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study. | 2 |
| 13 | 9 | |
| 14 | Phase I clinical trial of spirogermanium. | 29 |
| 15 | The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs. | 5 |
| 16 | 11 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.